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Abstract
Intraepithelial lymphocytes (IELs) bearing the cd T-cell receptor are a unique intestinal subset whose function remains
elusive. Here, we examine how they behave in AIDS and during various regimens of antiretroviral treatment in order to
obtain mechanistic insight into their adaptive or innate functional in vivo properties. IELs were studied by multimarker two-
colour immunofluorescence in situ staining. Consecutive duodenal biopsies were obtained from advanced infection-prone
HIV
+ patients (n=30). The systemic adaptive immune status was monitored by determining T-cell subsets and
immunoglobulins in peripheral blood. The cd IEL ratio (median 14.5%, range 1.5–56.3%) was significantly increased (p,0.02)
compared with that in clinically healthy HIV
2 control subjects (n=11, median 2.8%; range 0.3–38%), although the number
of cd IELs per mucosal length unit (U) only tended to be increased (4.0/U in HIV
+ versus 3.2/U in HIV
2subjects). Notably, the
total number of CD3
+ IELs was significantly reduced in AIDS (p,0.0001, 39.6/U in HIV
+ versus 86.4/U in HIV
2 subjects).
Almost 100% of the cd IELs were CD8
2 and they often expressed the Vd1/Jd1-encoded epitope (median 65.2%). HIV
+
patients on highly active antiretroviral therapy only tended to have a lower ratio of cd IELs (median 12.8%) than those
receiving no treatment (median 14.3%) or 1 nucleoside analogue (NA) (median 23.5%) or 2 NAs (median 13.0%). This
minimal variation among therapy groups, contrasting the treatment response of systemic and local adaptive immunity,
harmonizes with the novel idea derived from animal experiments that cd T cells are largely innate cells in first-line microbial
defence.
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Introduction
There is currently consensus that developing a human
immunodeficiency (HIV) vaccine will be essential to stop the
global acquired immunodeficiency syndrome (AIDS) epidemic [1],
but human trials based on parenteral immunization have yielded
disappointing results. Therefore, the general opinion is that more
basic science studies of HIV cell entry and mucosal immunology
are required to boost the development of an efficacious vaccine
[2,3]. Perhaps induction of a mucosal secretory immunoglobulin A
(IgA) antibodies together with a cytotoxic response in mucosal and
systemic CD8
+ T cells is what novel efforts should aim at [4,5]. In
addition, it may be possible to reinforce innate immune
mechanisms to enhance mucosal protection.
T cells expressing the cd T-cell receptor (TCR) are believed to
be critical in immune regulation, tumour surveillance and primary
immune responses. Studies of TCR-mediated selection of T cells
in mice support the view that some cd subsets are unconventional
and positively rather than negatively selected on cognate self
antigen [6,7]. However, recent findings have revealed effector
functions apparently reflecting a mix of innate programming and
acquired plasticity [8]. More than 20 years ago we reported a
striking increase of duodenal cd intraepithelial lymphocytes (IELs)
in coeliac disease [9], and a cd CD8
+ IEL subset in such patients
has recently been shown to have attributes of regulatory cells – at
least partly by secreting TGF-b upon NKG2A– HLA-E
interaction with intestinal epithelial cells [10].
We have also reported an increased proportion of duodenal cd
IELs in patients with hypogammaglobulinaemia associated with
mild to moderate intestinal villous atrophy [11] and in selectively
IgA-deficient subjects without infections [12]. We found in similar
studies of HIV
+ patients that the duodenal cd IEL proportion was
strikingly increased but, notably, decreased to normal levels in
terminal AIDS cases less than 7 months before death [13].
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29066Here, we retrospectively studied alterations in cd IELs by two-
colour immunofluorescence staining in duodenal tissue sections
from patients with late-stage HIV type 1-infection. We related the
distribution of these IELs to the number of B cells (CD19
+), T cells
(CD4
+ and CD8
+) and b2-microglobulin (b2-M) in peripheral
blood as well as to clinical manifestations, treatment combinations,
and various stages of disease progression. We had the opportunity
to study immune alterations in severely immunodeficient patients
during periods of simple treatment (1991–96), often with 1
nucleoside analogue (NA) or 2 NAs, compared with highly active
antiretroviral therapy (HAART) of more recent years. By
observing the response of IEL subsets – particularly the cd T
cells – compared with adaptive immunity markers, we hoped to
obtain more mechanistic insight into their in vivo functional nature
in humans as most of our current understanding of these unique
immune cells come from studies in mice.
Results
Distribution of cd intraepithelial lymphocytes
The total number of CD3
+ IELs per mucosal U was
significantly lower (p,0.0001) in the HIV
+ patients than in the
controls (39.6/U versus 86.4/U). There was a striking variability
among the patients as to the density of cd IELs (Fig. 1) but the
total number per mucosal length unit (U) tended to be increased
(median 4.0/U versus 3.2/U). Therefore, the average cd IEL ratio
(Fig. 2) in the 30 HIV
+ patients (median 14.5%, range 1.5–56.3%)
was significantly increased (p,0.02) compared with values in the
healthy controls (median 2.8%, range 0.3–38%). Autofluorescence
in some of the old biopsies limited countable areas, and two
patients were excluded from IEL counts/U. However, the ratios
and numbers of cd IELs were well correlated (r=0.74),
substantiating the validity of the recording methods.
Regarding the clinical subgroups of HIV
+ patients, those with
B-cell lymphoma, herpes simplex II infection, or with Mycobacte-
rium avium intracellulare complex (MAC) infection had particularly
high ratios of cd IELs (Fig. 3). We also observed relatively high
ratios in two patients with cytomegalovirus (CMV) infection or
tuberculous lymphadenitis, whereas those with Candida infection
showed a wide range (4.5%–56.3%). The lowest cd IEL ratios
were seen in HIV
+ patients suffering from toxoplasmosis, Kaposi’s
sarcoma, or hepatitis C virus infection.
When we related the cd IELs to different antiretroviral therapy,
the highest ratios were seen in HIV
+ patients on single medication
(1 NA, median 23.5%; p,0.04 versus controls); these patients were
the earliest included ones (before April, 1996) and often had
intercurrent infections. The cd IEL ratios were also increased in
untreated patients (median 14.3%; p,0.008) and in those on
double nucleoside analogues (2 NAs, median 13.0%; p,0.04),
whereas those on triple combination therapy (HAART, median
12.8%) did not reach significance (p=0.08) due to widely scattered
ratios (Fig. 4).
As mentioned above, the total number of cd IELs tended to be
increased despite a highly significant decrease of the total number
of CD3
+ IEL/U in the HIV
+ patients as a group (medians 31.7–
45.7/U) compared with healthy controls (Fig. 4). In our previous
studies we classificated three HIV
+ subgroups according to length
of survival after biopsy [13,14], but this clinical grouping did not
provide a better cd IEL discrimination. It should be noted,
however, that the 7 premortal patients died of diseases unrelated to
AIDS, e.g. cerebral haemorrhagia, cardiac left ventricle dysfunc-
tion, aortic valve stenosis and neurolues.
Two-colour staining for CD8 revealed that almost all cd IELs
were CD8
2 (median 100%, range 85–100%), as previously
reported in coeliac disease (median 90%) [9] and primary
immunodeficiencies (median 94–99%) [11,12] and also in healthy
Figure 1. Paired immunofluorescence staining (merges) for CD3 (green) and cdTCR (red). The left panel shows a sectioned duodenal villus
from an HIV
+ patient who had retained an abundance of intraepithelial lymphocytes (IELs) which are mainly CD3
+cd TCR
2 (presumably abTCR
+CD8
+)
and only few are CD3
+cdTCR
+ (yellow; median 14%). The right panel shows comparable field from an HIV
+ patient with depletion of IELs but with
highly increased CD3
+cdTCR
+ ratios (yellow; median 60%). In both sections some nonspecifically stained deposits are seen in the lamina propria,
while the epithelium is visualized due to autofluorescence (which increased during storage of the frozen tissue samples).
doi:10.1371/journal.pone.0029066.g001
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HIV
+ patients (median 65.2%, range 21.7–100%) expressed the
Vd1/Jd1-encoded epitope revealed by mAb dTCS-1 – almost
identical to that in patients with coeliac disease (67%) [9], primary
immunodeficiencies (63–84%) [11,12], and healthy controls (75%)
[9,11]. No difference was seen among the subgroups of HIV
+
patients.
Infection parameters in peripheral blood related to cd
IELs
When circulating T-cell subsets in HIV
+ patients were
compared with healthy blood donors [15], a tendency to reduced
median numbers of CD8
+ cells (0.36610
9/l; range, 0.057–
1.67610
9/l versus 0.405610
9/l; range, 0.18–1.23610
9/l) was
observed while the CD4 counts were, as expected, significantly
(p,0.0001) reduced (0.020610
9/l; range, 0.0012–0.25610
9/l
versus 0.815610
9/l; range, 0.5–1.58610
9/l) – particularly in late
stage (Group II, 0.019610
9/l) and preterminal (Group III,
0.015610
9/l) AIDS patients.
Plasma HIV RNA (n=12) increased as expected towards the
end of life: Group I, 57000 copies/ml; Group II, 70000 copies/ml;
and Group III, 191000 copies/ml. We observed a trend towards a
higher CD4 count (0.060610
9/l, n=9versus 0.022610
9/l) and a
lower median plasma HIV RNA level (76000 copies/ml) in
patients receiving HAART.
No relationship was seen between the relative (Fig. 2) or
absolute (Fig. 4) numbers of cd IELs and the level of circulating
CD4
+ or CD8
+ T cells, the CD4:CD8 ratio or the B-cell number
in peripheral blood.
Serum immunoglobulins and b2 microglobulin
Hypergammaglobulinaemia was seen in 16 of the HIV
+
patients, mostly IgG (18.3 g/l; range, 8.7–44.6 g/l) dominated
by IgG1 (median, 11.2 g/l) and IgG3 (median, 1.8 g/l). There was
only a slight increase of IgA (median 3.5 g/l) and also IgM
(median, 1.5 g/l) was within normal limits. Compared with IgA in
untreated HIV
+ patients (median, 4.2 g/l), the level tended to be
decreased in patients on HAART (median, 3.1 g/l), similarly to
what we observed for duodenal IgA-producing plasma cells [14].
The b2-M level in HIV
+ patients (median, 3.7 mg/l; n=28) was
significantly increased (p,0.0001) compared with healthy controls
(median, 1.2 mg/l). No relationship was observed between serum
b2-M and circulating CD4
+ or CD8
+ cells, duodenal cd IELs or
any of the other immunological variables.
Long-time survivors
Three of the ten ARC/AIDS patients were so-called long-time
survivors (LTSs), living for 15–17 years after becoming HIV
+.
Only one of them received HAART and one was not treated at all.
Two of them were IVDAs and one was homosexual. Compared
with the HIV
+ patients as a group, they had lower median ratios
and numbers of duodenal cd IELs (7.1%, number 1.6/U), average
levels of circulating CD4
+ T cells, and mostly low serum IgG1.
One 38-year old female IVDA received stavudine (d4T) and
methadone. She suffered from wasting syndrome, AIDS dementia,
and chronic hepatitis B and C virus infection, and had remarkably
elevated serum immunoglobulins (especially IgG, 33.6 g/l) and
relatively many duodenal IgG-producing plasma cells (15.2%),
mainly of the IgG1 subclass [14]. We found elevated duodenal cd
IELs in this LTS (19.2%, number 5.5/U). All other immunological
variables were near the average values.
Discussion
More information is needed about the compartmentalized
distribution of lymphoid and accessory immune cells in human
intestinal mucosa to enable modulation of local immunity in a
rational manner [16]. This has been emphasized in face of the
failure of parenteral vaccines to reinforce immunity at the site of
HIV entry [1–5]. However, ethical restrictions in sampling
mucosal tissue from AIDS patients prohibit functional studies of
local immune cells ex vivo, thus limiting our efforts to obtain
mechanistic insight to observing their treatment response in vivo.
Here, we confirmed the relative increase of duodenal cd IELs in
HIV patients, as seen in our previous study of patients included
before 1996 [13]. A concurrent study did not find elevated cd IELs
in HIV
+ patients, whether they had diarrhoea or not [17]. This
discrepancy might have a technical origin as the study was partly
based on flow-cytometric analyses of dispersed cells. We
performed quantitative in situ cell phenotyping and enumeration
with a careful morphometric approach. In our HIV
+ patients
especially high cd IEL ratios were associated with intercurrent B
cell lymphoma, herpes simplex II infection, MAC infection, CMV
infection, and tuberculous lymphadenitis.
Our results suggested that a relative expansion of the cd IEL
fraction occurs in advanced AIDS at the same time as the total
IEL population is reduced. Most human IELs are memory ab
CD8
+ T cells [18,19]; based on recently published immunization
experiments (both in humans and mice) [20], their long-term
residence at body surfaces, including the gut epithelium, may
depend on repetitive inductive activity in peripheral lymphoid
organs. It has been reported that viral control and early HIV
disease progression is associated with a synchronous differentiation
of the HIV-specific and total CD8
+ memory cell populations [21].
Figure 2. Scatter diagram of the percentage of duodenal cd
IELs in HIV
+ patients compared with HIV
2 control subjects.
Median ratios are represented by vertical columns (*: p,0.02, Mann-
Whitney two-tailed test).
doi:10.1371/journal.pone.0029066.g002
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+
helper T cells deteriorate in AIDS, chronic infectious stimuli are
apparently unable to maintain the dominating ab CD8
+ IEL
population due to lack of T-cell homing to the intestinal mucosa
[22]. Thus, there must be other rules for cd IELs which are
maintained or expanded in response to opportunistic micro-
Figure 4. The cd IEL subset remains elevated in AIDS patients despite antiretroviral treatment. Scatter diagram shows cd:CD3 ratios for
duodenal IELs, cd IEL numbers per mucosal unit (above 1 mm of muscularis mucosae), and numbers of CD3
+ IELs per mucosal unit in HIV
+ patients –
all variables displayed according to administered antiretroviral treatment compared with no treatment and with data from HIV
2 control subjects.
Medians are represented by vertical columns. NA, nucleoside analogue; HAART, highly active antiretroviral therapy.
doi:10.1371/journal.pone.0029066.g004
Figure 3. Scatter diagram of the percentage of duodenal cd IELs in relation to clinical features of individual HIV
+ patients. Median
ratios are represented by horizontal columns. CMV, cytomegalovirus infection; MAC, Mycobacterium avium intracellulare complex.
doi:10.1371/journal.pone.0029066.g003
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treatment did not reduce the response. This was in contrast to the
expanded IgA
+ duodenal plasma cell population that was
significantly decreased by HAART in virtually the same patient
material [14].
The function of cd IELs is probably not limited to first-line
defence. In mice the activation of cd T cells sometimes follows that
of ab T cells, and the cd T cells may mainly contribute to immune
regulation and tissue repair [23]. The common overlap of cd
TCR-directed pathogen-encoded epitopes with molecules ex-
pressed by ‘‘stressed’’ host cells has fuelled the view that cd T-cell
responses are driven by lack of tissue homeostasis (inflammation,
cell damage or transformation) rather than by microbial challenges
[23]. In mice, it has been shown that cd T cells express the toll-like
receptors TLR1 and TLR2, as well as dectin-1, and respond to
microbial products [24]. In addition, they express the aryl
hydrocarbon receptor (AhR) and can therefore receive other
environmental signals that may shape their functional capacity,
including the production of the IL-17 cytokine [24]. Thus, these
cells do not necessarily need TCR engagement but can be
triggered by their innate receptors or, alternatively, by the
cytokines IL-1 or IL-23 derived from activated macrophages or
dendritic cells [25].
If it can be shown that human cd IELs have immune
modulating properties similar to murine cd T cells, this would fit
with the fact that they are not negatively affected by deterioration
of the adaptive immune system in advanced AIDS, but rather
expand in such HIV
+ patients. Interestingly, it was recently shown
that murine cd IELs are a self-renewing population with little
migration and recirculation out of their specialized niche, whereas
peripheral cd IELs are highly motile [26].
We have earlier reported a marked decrease of duodenal cd
IELs in premortal AIDS patients [13]. A combined deficiency of
cd IELs and IgA-producing plasma cells at the end stage of AIDS
could in part be responsible for the fatal result. In the present study
we could not show this; but it should be noted that most of the
preterminal patients included here died of diseases unrelated to
AIDS. There was a strikingly variable positive effect of HAART
on the cd IEL counts in the AIDS patients, although immune
reconstitution was usually confirmed by favourable CD4-cell
counts and plasma HIV RNA levels in peripheral blood.
Serum levels of b2-M and neopterin (an intermediate in the
biosynthesis of tetrahydro-biopterin), which are markers of
immunostimulation [27], showed an inverse correlation with
duodenal cd IELs in end-stage AIDS in our previous study [13]. A
similar strong tendency of increasing b2-M concentrations towards
the end of life was not observed in the present study. This could
reflect the beneficial effect of HAART in advanced AIDS. One of
the three LTSs showed particularly good prognosis (undetectable
HIV RNA level) and had elevated serum IgG and duodenal IgG
+
plasma cells (especially IgG1). This suggested complement-
activating local immunity – a response also noted in other studies
[28,29]. Additionally, we found raised ratio and number of cd
IELs (19.2%, 5.5/U) in this patient, contributing to the idea that
these cells exert immunoregulatory functions.
There is a recent focus on the intestinal epithelial barrier as an
important variable in HIV infection. Pigtail macaques (PTMs)
rapidly progress to AIDS after simian immunodeficiency virus
(SIV) infection. The explanation seems to be that uninfected
PTMs commonly show damage to their intestinal barrier [30].
This results in microbial translocation and deleterious immune
activation both locally and systemically; a higher frequency of
CD4
+ memory/effector T cells ensues, and these cells are the
primary target for SIV/HIV infection.
Th17 cells are important in microbial defence by attracting
neutrophils and maintaining the mucosal barrier; but these CD4
+
cells are preferentially lost during HIV infection [31], although
they may be restored by HAART [32]. Importantly, however, cd
T cells may respond more rapidly with IL-17 secretion because of
their innate nature [24,25,32], and therefore be compensating for
the Th17 cell loss. Moreover, there is experimental evidence in
mice that cd T cells may amplify the function of Th17 cells [25]
and inhibit regulatory cells T (Treg) cells [33]. Putative Treg cells
(CD4
+CD25
+FOXP3
+) in peripheral blood may be increased in
HIV
+ patients and dampen various defences against the virus; but
decrease of Treg cells has been reported in chronic HIV infection
[34,35]. Thus, it remains unresolved whether Treg cells are
protective or detrimental in HIV
+ patients. Also the balance
between Th17 cells, cd T cells and Treg cells shows a complexity
afflicted with many uncertainties [36]. Nevertheless, a recent study
reported fewer Treg cells in rectosigmoid mucosal biopsies of HIV
long-term ‘‘controllers’’ than ‘‘non-controllers’’ [37].
Taken together, it remains unknown to what extent these
immunological variables influence the course of HIV infection.
However, cd T cells with specificity for Candida albicans, and
bearing the Vd1 TCR chain as well as possessing cytoplasmic IL-
17, have been identified in peripheral blood of HIV
+ patients [38].
Whether these cells have similar functional properties as cd IELs
remains uncertain. We observed a relative expansion of duodenal
Vd1
+ cd IELs in AIDS patients, even in those receiving
antiretroviral therapy. This probably reflected an intensified
innate response to an increased luminal load of microbial
components. Secondary intestinal infections are common in
AIDS, and it is important to define how the mucosal defence
behaves in these patients. A better delineation of intestinal HIV
immunology, including the late stage-induced local response, is
crucial to this end.
Materials and Methods
Biological samples
Duodenal biopsy specimens and peripheral blood were collected
consecutively during the period 1991–98 from 30 patients infected
with HIV type 1 (5 women: median age, 33 years and range, 26–
40 years; and 25 men: median age, 39 years and range, 26–52
years); 18 were homosexual men, 7 intravenous drug abusers
(IVDAs), and 5 had experienced heterosexual virus transmission in
Africa (Table S1). Informed verbal consent was obtained from all
patients. The biopsy material was derived from the Diagnostics
and Treatment Biobank of the Oslo University Hospital. This
collection of biological material intended for clinical examination,
diagnostics and treatment does not require explicit informed
consent according to The Norwegian Treatment Biobank Act
2003.
In addition, similar biopsy and blood samples were obtained
from 11 immunologically intact HIV
2 controls (seven females and
four males; median age 21 years and range, 4.5–76 years) with no
histological abnormalities in duodenal mucosa. Dyspepsia, growth
retardation, irritable bowel syndrome, and hypothyroid disease
were the reasons for endoscopic examination in a minority of the
subjects as we also included volunteers (health workers) with no
symptoms. Part of the same control material has been used in
previous studies with informed written consent [11–13], and the
Regional Ethics Committee approved the inclusion of additional
controls to replace exhausted material.
All HIV
+ patients had serum IgG antibodies to HIV type 1 as
determined by ELISA (Organon Teknika, Boxtel, The Nether-
lands; or Abbott, Wiesbaden-Delkenheim, Germany) and this was
Intraepithelial Gut cd T Cells in AIDS
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clinically classified according to the criteria of the Centers for
Disease Control and Prevention (CDC), Atlanta (GO, USA), 5
subjects were staged in group CDC IVA/B, 23 in group CDC
IVC1, and 2 in group CDC IVD – the latter 25 fulfilling
diagnostic criteria for full-blown AIDS. Because most of the
patients were classified as having late-stage AIDS, CD4
+ T-cell
counts did not differ much. Median survival time after the first
positive HIV test was 81 months (range 11–156 months; n=20).
Seven patients could retrospectively be defined as premortal due to
death within 7 months (six homosexual men, one raped female
refugee). However, they died mainly of diseases unrelated to
AIDS, e.g. cerebral haemorrhagia, cardiac left ventricle dysfunc-
tion, aortic valve stenosis and neurolues.
Clinical features
All HIV
+ patients suffered from different on-going opportunistic
and/or non-opportunistic infections; only one of them had skin or
mucosal lesions consistent with Kaposi’s sarcoma, and one had
non-Hodgkin malignant lymphoma. Eight of the patients had
chronic intermittent diarrhoea, of which two had cryptosporidi-
osis, one systemic CMV infection, and four herpes simplex type II
infection. Altogether twelve patients had oral and/or oesophageal
candidiasis, three suffered from MAC infection and two from
wasting (.10% unwanted weight loss). Only one of these patients
had duodenitis with histological signs of moderate, chronic
inflammation. Other serious infections such as Pneumocystis carinii
pneumonia was found in one patient, two had toxoplasmosis
(encephalitis), two chronic hepatitis C virus infection and one
tuberculous lymphadenitis (Table S1).
Four patients still received antiretroviral monotherapy with
zidovudine (ZDV) at the time of sampling (1995–96) while eight
used two other NAs such as didanosine (DDI) and/or stavudine (d4T)
as well (Table S1). Ten patients tolerated satisfactorily combination
therapy with one of these drugs together with lamivudine (3TC) and
HIV protease inhibitors (PI) such as indinavir (Crixivan) or nelfinavir
(Viracept), constituting HAART, whereas eight others had discon-
tinued all antiretroviral treatment because of intolerable side effects.
None received immunoglobulin replacement therapy.
Quantification of Ig isotypes, B cells, T-cell subsets, b2-
microglobulin and HIV RNA in peripheral blood
Measurements of serum IgG, IgA, and IgM were performed by
nephelometry with commercial standards (Behringwerke, Mar-
burg, Germany), while quantification of serum IgG subclasses was
performed with monoclonal antibodies (mAbs) in commercial kits
(The Binding Site, Birmingham, UK). The blood samples were
collected as near the time of biopsy as possible (usually within 1 to
2 hours before) and analysed on the same day, or frozen at 220uC
or 270uC for later analyses.
CD19
+ B cells and CD4
+/CD8
+ T cells in peripheral blood
were enumerated by a standard flow cytometric method. b2-M
was measured by a microparticle enzyme immunoassay (Abbott
IMX; Abbott laboratories, Abbott Park, IL, USA). HIV RNA was
measured by a reverse transcriptase-polymerase chain reaction
(RT-PCR) assay (Amplicor HIV-1 Monitor, Roche Diagnostic
System, Brachburg, NJ, USA). The detection limit of the kit was
400 HIV-1 RNA copies/ml; lower values were also included. This
methodology was only available after August 1996 in our hospital.
Tissue sample processing
Multiple mucosal biopsy specimens (n=8–10) were obtained
endoscopically (Olympus GIF K10) from the distal duodenum.
Endoscopical signs of chronic inflammation were occasionally
observed in the distal oesophageal (n=3), prepyloric gastric (n=1)
or duodenal mucosa (n=2). Two specimens from each subject
were processed for conventional histological evaluation. Other
tissue specimens were fixed in 2% (w/v) paraformaldehyde for
electron-microscopic evaluation or processed by snap-freezing in
liquid nitrogen for immunohistochemistry (see below). All
gastrointestinal endoscopies were performed in the HIV
+ patients
solely for clinical indications, mostly to evaluate their symptoms
such as dysphagia, diarrhoea or cachexia. Ethical reasons
prevented us from obtaining additional biopsies.
Histological evaluation
A tissue section from each biopsy series was stained with
haematoxylin and eosin for histological evaluation. In addition,
scanning electron microscopy was performed to classify villus
changes as previously described [11]. Such combined evaluation
showed normal villi in all 30 HIV
+ patients. Only two of them had
histological signs of moderate, chronic duodenal inflammation. All
control subjects had histologically normal duodenal biopsies.
Two- or three-colour immunohistochemical staining
Serial cryosections were cut at 6 mm and incubated for 1 hour
at ambient temperature with pairs of unlabelled murine mAbs of
the following human specificities: d chain of cd TCR (TCRd1,
IgG1, 1/20; T Cell Sciences Inc., Cambridge, MA, USA) and
CD3 (clone RIV9, IgG3, 1/10; Sanbio, Am Uden, The Nether-
lands); d chain of cd TCR and the a chain of CD8 (BMA-081,
IgG2a, 1/40; Behringwerke, Marburg, Germany); CD4 (anti-Leu-
3a and -3b, IgG1, 1/40; Becton Dickinson, Mountain View, CA,
USA) and CD3 (RIV9, IgG3, 1/10; Sanbio); and CD8 (anti-Leu-
2b, IgG2a, 1/20; Becton Dickinson) mixed with BMA-081 (IgG2a,
1/80) and CD3 (anti-Leu-4, IgG1, 1/80; Becton Dickinson).
Secondary antibody reagents were various combinations of
biotinylated and fluorescein isothiocyanate-conjugated goat IgG
(0.01 to 0.05 g/litre) with specificity for mouse IgG1, IgG2a, or
IgG3 (Southern Biotechnology, Birmingham, ALA, USA). These
reagents were applied for 1.5 hour, and then streptavidin-Texas
red (0.0025 g/litre; Bethesda Research Laboratories, Gaithers-
burg, MD, USA) was applied for 30 min. Human IgG at 0.8 g/
litre (Kabi Vitrum, Stockholm, Sweden) was added to the goat
reagents to block species cross-reactivity [9]. Because mAb TCRd1
reacts with all cd T cells, sequential staining was performed as
detailed elsewhere [9] to examine the subset expressing the Vd1/
Jd1-encoded epitope for mAb dTCS-1 (IgG1; T Cell Sciences).
Fluorescence microscopy and cell counting
Immunofluorescence was examined at a magnification of 6300
in a Nikon microscope (Eclipse E600; ocular grid; Nikon, CFI)
equipped with a Ploem-type vertical illuminator with interference
filters for selective observation of red, green, or blue emission. The
results were recorded on Ectachrome professional 800/1600 ASA
daylight film. All sections were examined blinded by the same
investigator. The percentage distribution of cd IELs was
determined by evaluating every CD3
+ IEL for cd TCR expression
(Fig. 1). Also coexpression of CD8 and Vd1/Jd1o ncd IELs was
similarly examined.
The total number of CD3
+ and cd IEL was related to a 316-mm
grid width, including all parts of the epithelium from the luminal
face to the muscularis mucosae. The number of CD3
+ and cd IELs
in four such defined parallel areas was determined and calculated
to be expressed per millimetre of muscularis mucosae (mucosal
length unit, U). When necessary, cytokeratin immunostaining was
used to outline the epithelial compartment; a rabbit antiserum (1/
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acid-conjugated goat anti-rabbit IgG (1/20; Vector Laboratories,
Burlingame, CA, USA).
Control reference data
The ratios of cd IELs as well as the numbers of CD3
+ and cd
IELs per mucosal U were determined as described above in
histologically normal duodenal mucosa of the eleven HIV
2
control subjects. Reference data were available in our laboratory
for the normal expression of the Vd1/Jd1-encoded epitope on cd
IELs [9]. Normal CD4:CD8 T-cell ratios for duodenal lamina
propria and epithelial compartments were based on published data
[40].
As normal reference data for circulating lymphocyte subsets, we
used results from healthy (HIV
2) blood donors (n=60) [15]
recorded as described previously [41]. Reference data from blood
donors were also available for serum concentrations of b2-M
(n=18). The HIV RNA level in normal controls was set at ,400
copies/ml plasma.
Statistical analysis
Statistical calculations were based on the software program
SPSS (Chicago, IL) while the Mann-Whitney 2-tailed test for
unpaired samples was used for comparison between various
categories of HIV
+ patients and control subjects. Results are
presented as median and observed range. Differences between
groups were considered statistically significant at p,0.05.
Correlations between mucosal CD3
+ IELs or cd IELs and
circulating T-cell subsets or b2-M in the HIV
+ patients and the
HIV
2 controls were calculated by the Spearman rank correlation
test (SPSS), as was the relationship between the proportions and
numbers of cd IELs. The reproducibility of in situ T-cell
enumerations by paired immunofluorescence staining was excel-
lent as documented in our previous studies [9,11,12].
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